<p>随着美国股市逐渐上涨，标准普尔 500 指数达到新高，投资者密切关注美联储的信号和可能影响未来趋势的主要科技公司财报。在这样的背景下，便士股票——通常代表较小或较新的公司——继续为那些寻求低价增长机会的投资者提供引人注目的机会。尽管被视为一个小众领域，这些股票在拥有良好的财务健康和基本面时可以大放异彩，展现出潜在的上行空间，同时降低一些相关风险。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.86</td>
<td>$591.48M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.67</td>
<td>$614.83M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8033</td>
<td>$141.11M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.95</td>
<td>$499.74M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.40</td>
<td>$931.68M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9301</td>
<td>$6.69M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.75</td>
<td>$88.13M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.90</td>
<td>$12.14M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器中的 326 只股票的完整列表。</p>
<p>让我们回顾一些我们筛选出的显著股票。</p>
<h2>Definitive Healthcare (DH)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Definitive Healthcare Corp. 提供一个 SaaS 医疗商业智能平台，业务遍及美国和国际市场，市值为 3.4563 亿美元。</p>
<p><strong>运营：</strong> 该公司从其互联网信息提供商部门产生的收入为 2.4228 亿美元。</p>
<p><strong>市值：</strong> 3.4563 亿美元</p>
<p>Definitive Healthcare Corp. 的市值为 3.4563 亿美元，运营一个 SaaS 医疗平台，尽管被认为是亏损的，但由于正的自由现金流，保持着超过三年的强现金流。该公司已成功用其资产覆盖短期和长期负债，尽管近期出现亏损，但显示出财务稳定性。其交易价格低于估计公允价值的 55%，与同行相比显示出良好的相对价值。最近的财报显示，与之前的时期相比，亏损有所减少，但短期内仍难以实现盈利。近期的股票回购并未显著稀释股东价值。</p>
<ul>
<li>点击探索我们在 Definitive Healthcare 财务健康报告中的详细发现。</li>
<li>通过我们的公司盈利预估报告，获取 Definitive Healthcare 的前景和预期表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis"/></p>
<p>DH 财务状况分析截至 2026 年 1 月</p>
<h2>Duluth Holdings (DLTH)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Duluth Holdings Inc. 在美国运营，销售男女休闲服、工作服、户外服装及配饰，市值为 8,888 万美元。</p>
<p><strong>运营：</strong> 该公司的在线零售收入为 5.9056 亿美元。</p>
<p><strong>市值：</strong> 8,888 万美元</p>
<p>Duluth Holdings Inc. 的市值为 8,888 万美元，面临挑战，因为它仍处于亏损状态，并且在过去五年中亏损有所增加。尽管如此，该公司的短期资产超过其短期和长期负债，显示出一定的财务稳定性。最近的财报显示，与之前的时期相比，亏损有所减少，尽管销售额同比下降。该公司下调了 2026 财年的净销售指导，反映出持续的运营困难。虽然交易价格几乎低于估计公允价值的 90%，显示出潜在的上行空间，但高波动性和现金流覆盖债务不足仍然是投资者的担忧。</p>
<ul>
<li>通过我们的综合资产负债表健康报告，深入了解 Duluth Holdings 的复杂性。</li>
<li>通过审查我们的增长报告，了解 Duluth Holdings 的盈利前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis"/></p>
<p>DLTH 财务状况分析截至 2026 年 1 月</p>
<h2>Prelude Therapeutics (PRLD)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家临床阶段的精准肿瘤学公司，致力于为服务不足的患者发现和开发新型癌症药物，市值为 1.6727 亿美元。</p>
<p><strong>运营：</strong> 该公司从其生物技术（初创企业）部门产生的收入总计为 1050 万美元。</p>
<p><strong>市值：</strong> 1.6727 亿美元</p>
<p>Prelude Therapeutics 的市值为 1.6727 亿美元，专注于精准肿瘤学领域，尽管在 2025 年第三季度报告了 650 万美元的销售额，但仍未产生收入。该公司无债务，短期资产超过负债，但由于波动性增加和截至 2025 年 9 月的现金流仅有七个月，面临挑战。最近的战略举措包括通过私募融资筹集 2500 万美元，以及与 Incyte 达成其 JAK2V617F 抑制剂项目的独家选择协议。尽管未盈利，但预计收益将以每年 55.66% 的速度显著增长，在高波动性中展现出潜在机会。</p>
<ul>
<li>在我们的财务健康报告中更详细地了解 Prelude Therapeutics 的潜力。</li>
<li>通过审查我们的增长报告，获取 Prelude Therapeutics 未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis"/></p>
<p>PRLD 财务状况分析截至 2026 年 1 月</p>
<h2>接下来该怎么办？</h2>
<ul>
<li>解锁更多宝藏！我们的美国便士股票筛选器为您挖掘了 323 家更多公司供您探索。点击这里揭开我们精心策划的 326 只美国便士股票名单。</li>
<li>寻找替代机会？我们发现 13 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单，免费获取。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

<p>随着美国股市的上涨，低价股吸引了投资者的关注。Definitive Healthcare 的市值为 3.4563 亿美元，运营着一个 SaaS 医疗平台，尽管尚未盈利，但显示出财务稳定性。Duluth Holdings 的市值为 8,888 万美元，面临着损失增加和销售下滑的挑战。Prelude Therapeutics 是一家临床阶段的肿瘤学公司，市值为 1.6727 亿美元，尚未产生收入，但尽管现金流有限，仍具有增长潜力。投资者被鼓励探索更多低价股以寻找增长机会</p>

<p>As the U.S. stock market edges higher with the S&amp;P 500 reaching new milestones, investors are keenly watching for signals from the Federal Reserve and major tech earnings that could influence future trends. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for those seeking growth at lower price points. Though considered a niche area, these stocks can shine when backed by solid financial health and fundamentals, presenting potential upside while mitigating some of the associated risks.</p>
<div class="lb-trans"><p>随着美国股市逐渐上涨，标准普尔 500 指数达到新高，投资者密切关注美联储的信号和可能影响未来趋势的主要科技公司财报。在这样的背景下，便士股票——通常代表较小或较新的公司——继续为那些寻求低价增长机会的投资者提供引人注目的机会。尽管被视为一个小众领域，这些股票在拥有良好的财务健康和基本面时可以大放异彩，展现出潜在的上行空间，同时降低一些相关风险。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.86</td>
<td>$591.48M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.67</td>
<td>$614.83M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8033</td>
<td>$141.11M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.95</td>
<td>$499.74M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.40</td>
<td>$931.68M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9301</td>
<td>$6.69M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.75</td>
<td>$88.13M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.90</td>
<td>$12.14M</td>
<td>✅ 2 ⚠️ 4 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.86</td>
<td>$591.48M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.67</td>
<td>$614.83M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8033</td>
<td>$141.11M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.95</td>
<td>$499.74M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.40</td>
<td>$931.68M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9301</td>
<td>$6.69M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.75</td>
<td>$88.13M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.90</td>
<td>$12.14M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 326 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器中的 326 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些我们筛选出的显著股票。</p>
</div><h2>Definitive Healthcare (DH)</h2>
<div class="lb-trans"><h2>Definitive Healthcare (DH)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Definitive Healthcare Corp. offers a SaaS healthcare commercial intelligence platform operating both in the United States and internationally, with a market cap of $345.63 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Definitive Healthcare Corp. 提供一个 SaaS 医疗商业智能平台，业务遍及美国和国际市场，市值为 3.4563 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $242.28 million from its Internet Information Providers segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其互联网信息提供商部门产生的收入为 2.4228 亿美元。</p>
</div><p><strong>Market Cap:</strong> $345.63M</p>
<div class="lb-trans"><p><strong>市值：</strong> 3.4563 亿美元</p>
</div><p>Definitive Healthcare Corp., with a market cap of US$345.63 million, operates a SaaS healthcare platform and is considered unprofitable, yet maintains a strong cash runway exceeding three years due to positive free cash flow. The company has managed to cover both short-term and long-term liabilities with its assets, suggesting financial stability despite recent losses. It trades at 55% below estimated fair value and shows good relative value compared to peers. Recent earnings reports indicate reduced losses compared to previous periods, but profitability remains elusive in the near term. Share buybacks have not significantly diluted shareholder value recently.</p>
<div class="lb-trans"><p>Definitive Healthcare Corp. 的市值为 3.4563 亿美元，运营一个 SaaS 医疗平台，尽管被认为是亏损的，但由于正的自由现金流，保持着超过三年的强现金流。该公司已成功用其资产覆盖短期和长期负债，尽管近期出现亏损，但显示出财务稳定性。其交易价格低于估计公允价值的 55%，与同行相比显示出良好的相对价值。最近的财报显示，与之前的时期相比，亏损有所减少，但短期内仍难以实现盈利。近期的股票回购并未显著稀释股东价值。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Definitive Healthcare's financial health report.</li>
<li>Gain insights into Definitive Healthcare's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Definitive Healthcare 财务健康报告中的详细发现。</li>
<li>通过我们的公司盈利预估报告，获取 Definitive Healthcare 的前景和预期表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis"/></p>
<p>DH Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>DH 财务状况分析截至 2026 年 1 月</p>
</div><h2>Duluth Holdings (DLTH)</h2>
<div class="lb-trans"><h2>Duluth Holdings (DLTH)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Duluth Holdings Inc. operates in the United States, selling casual wear, workwear, outdoor apparel, and accessories for men and women with a market capitalization of $88.88 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Duluth Holdings Inc. 在美国运营，销售男女休闲服、工作服、户外服装及配饰，市值为 8,888 万美元。</p>
</div><p><strong>Operations:</strong> The company's revenue from online retailing amounts to $590.56 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的在线零售收入为 5.9056 亿美元。</p>
</div><p><strong>Market Cap:</strong> $88.88M</p>
<div class="lb-trans"><p><strong>市值：</strong> 8,888 万美元</p>
</div><p>Duluth Holdings Inc., with a market cap of US$88.88 million, faces challenges as it remains unprofitable and has seen increased losses over the past five years. Despite this, the company's short-term assets exceed both its short and long-term liabilities, indicating some financial stability. Recent earnings reports show reduced losses compared to previous periods, though sales have declined year-over-year. The company lowered its net sales guidance for fiscal 2026, reflecting ongoing operational difficulties. While trading at nearly 90% below estimated fair value suggests potential upside, high volatility and insufficient cash flow coverage of debt remain concerns for investors.</p>
<div class="lb-trans"><p>Duluth Holdings Inc. 的市值为 8,888 万美元，面临挑战，因为它仍处于亏损状态，并且在过去五年中亏损有所增加。尽管如此，该公司的短期资产超过其短期和长期负债，显示出一定的财务稳定性。最近的财报显示，与之前的时期相比，亏损有所减少，尽管销售额同比下降。该公司下调了 2026 财年的净销售指导，反映出持续的运营困难。虽然交易价格几乎低于估计公允价值的 90%，显示出潜在的上行空间，但高波动性和现金流覆盖债务不足仍然是投资者的担忧。</p>
</div><ul>
<li>Navigate through the intricacies of Duluth Holdings with our comprehensive balance sheet health report here.</li>
<li>Understand Duluth Holdings' earnings outlook by examining our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合资产负债表健康报告，深入了解 Duluth Holdings 的复杂性。</li>
<li>通过审查我们的增长报告，了解 Duluth Holdings 的盈利前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis"/></p>
<p>DLTH Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>DLTH 财务状况分析截至 2026 年 1 月</p>
</div><h2>Prelude Therapeutics (PRLD)</h2>
<div class="lb-trans"><h2>Prelude Therapeutics (PRLD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $167.27 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家临床阶段的精准肿瘤学公司，致力于为服务不足的患者发现和开发新型癌症药物，市值为 1.6727 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Biotechnology (Startups) segment, totaling $10.5 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其生物技术（初创企业）部门产生的收入总计为 1050 万美元。</p>
</div><p><strong>Market Cap:</strong> $167.27M</p>
<div class="lb-trans"><p><strong>市值：</strong> 1.6727 亿美元</p>
</div><p>Prelude Therapeutics, with a market cap of US$167.27 million, operates in the precision oncology space and remains pre-revenue despite reporting US$6.5 million in sales for Q3 2025. The company is debt-free with short-term assets exceeding liabilities, yet faces challenges due to increased volatility and a limited cash runway of seven months as of September 2025. Recent strategic moves include a private placement raising US$25 million and an exclusive option agreement with Incyte for its JAK2V617F inhibitor program. Despite unprofitability, earnings are forecasted to grow significantly at 55.66% annually, presenting potential opportunities amidst high volatility.</p>
<div class="lb-trans"><p>Prelude Therapeutics 的市值为 1.6727 亿美元，专注于精准肿瘤学领域，尽管在 2025 年第三季度报告了 650 万美元的销售额，但仍未产生收入。该公司无债务，短期资产超过负债，但由于波动性增加和截至 2025 年 9 月的现金流仅有七个月，面临挑战。最近的战略举措包括通过私募融资筹集 2500 万美元，以及与 Incyte 达成其 JAK2V617F 抑制剂项目的独家选择协议。尽管未盈利，但预计收益将以每年 55.66% 的速度显著增长，在高波动性中展现出潜在机会。</p>
</div><ul>
<li>Take a closer look at Prelude Therapeutics' potential here in our financial health report.</li>
<li>Gain insights into Prelude Therapeutics' future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更详细地了解 Prelude Therapeutics 的潜力。</li>
<li>通过审查我们的增长报告，获取 Prelude Therapeutics 未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis"/></p>
<p>PRLD Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>PRLD 财务状况分析截至 2026 年 1 月</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该怎么办？</h2>
</div><ul>
<li>Unlock more gems! Our US Penny Stocks screener has unearthed 323 more companies for you to explore.Click here to unveil our expertly curated list of 326 US Penny Stocks.</li>
<li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁更多宝藏！我们的美国便士股票筛选器为您挖掘了 323 家更多公司供您探索。点击这里揭开我们精心策划的 326 只美国便士股票名单。</li>
<li>寻找替代机会？我们发现 13 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容为一般性信息。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

Definitive Healthcare 及其他两个有前景的便士股